Basic Materials [ 12/13 ] | Specialty Chemicals [ 101/163 ]
NASDAQ | Common Stock
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide.
It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
The Human Nutrition & Health segment supplies ingredients in the food and beverage industry.
Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates.
This segment also offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications.
The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health.
The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices.
This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops.
It sells its products through sales force, independent distributors, and sales agents.
The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 3, 24 | 1.03 Increased by +9.57% | 0.98 Increased by +5.10% |
| Feb 16, 24 | 0.95 Increased by +1.06% | 0.93 Increased by +2.15% |
| Oct 27, 23 | 1.04 Increased by +4.00% | 0.97 Increased by +7.22% |
| Jul 28, 23 | 1.06 Decreased by -0.93% | 0.84 Increased by +26.19% |
| Apr 28, 23 | 0.94 Decreased by -8.74% | 0.70 Increased by +34.29% |
| Feb 24, 23 | 0.94 Increased by +10.59% | 0.83 Increased by +13.25% |
| Nov 4, 22 | 1.00 Increased by +8.70% | 0.85 Increased by +17.65% |
| Jul 29, 22 | 1.07 Increased by +15.05% | 0.91 Increased by +17.58% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 239.66 M Increased by +3.06% | 28.99 M Increased by +27.64% | Increased by +12.09% Increased by +23.84% |
| Dec 31, 23 | 228.70 M Decreased by -1.65% | 26.65 M Increased by +24.49% | Increased by +11.65% Increased by +26.57% |
| Sep 30, 23 | 229.95 M Decreased by -5.86% | 29.07 M Increased by +15.15% | Increased by +12.64% Increased by +22.32% |
| Jun 30, 23 | 231.25 M Decreased by -2.30% | 30.11 M Increased by +1.10% | Increased by +13.02% Increased by +3.48% |
| Mar 31, 23 | 232.54 M Increased by +1.60% | 22.71 M Decreased by -21.50% | Increased by +9.77% Decreased by -22.74% |
| Dec 31, 22 | 232.53 M Increased by +9.10% | 21.41 M Decreased by -14.20% | Increased by +9.21% Decreased by -21.36% |
| Sep 30, 22 | 244.27 M Increased by +23.45% | 25.25 M Increased by +0.94% | Increased by +10.34% Decreased by -18.23% |
| Jun 30, 22 | 236.69 M Increased by +16.96% | 29.78 M Increased by +31.02% | Increased by +12.58% Increased by +12.02% |